leap therapeutics (nasdaq: lptx) is a clinical-stage biopharmaceutical company acquiring and developing novel therapeutics at the leading edge of cancer research. for more information about leap therapeutics, visit http://www.leaptx.com or our public filings with the sec that are available via edgar at http://www.sec.gov or via http://www.investors.leaptx.com.
Company profile
Ticker
LPTX
Exchange
Website
CEO
Doug E. Onsi
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
Dekkun Corp
SEC CIK
Corporate docs
Subsidiaries
GITR, Inc. • Leap Securities Corp. • HealthCare Pharmaceuticals Pty Ltd. • Flame Biosciences LLC ...
LPTX stock data
Latest filings (excl ownership)
8-K
Leap Therapeutics Announces $40 Million Private Placement
11 Apr 24
S-3
Shelf registration
18 Mar 24
8-K
Leap Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results
18 Mar 24
10-K
2023 FY
Annual report
18 Mar 24
S-8
Registration of securities for employees
26 Jan 24
8-K
Other Events
23 Jan 24
8-K
Leap Therapeutics to Present New Clinical Data from Part A of DeFianCe Study
16 Jan 24
8-K
Other Events
12 Dec 23
8-K
Leap Therapeutics Reports Third Quarter 2023 Financial Results
13 Nov 23
10-Q
2023 Q3
Quarterly report
13 Nov 23
Latest ownership filings
SC 13G
GILEAD SCIENCES, INC.
19 Apr 24
3
Initial statement of insider ownership
19 Apr 24
SC 13G/A
PERCEPTIVE ADVISORS LLC
14 Feb 24
4
Nissim Mashiach
31 Jan 24
4
Thomas John Dietz
31 Jan 24
4
Richard Schilsky
31 Jan 24
4
Christine Granfield
31 Jan 24
4
Jason Baum
31 Jan 24
4
Christian M Richard
31 Jan 24
4
John Mark O'Mahony
31 Jan 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | Dec 20 | Dec 19 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 80.74 mm | 80.74 mm | 80.74 mm | 80.74 mm | 80.74 mm | 80.74 mm |
Cash burn (monthly) | 3.56 mm | (no burn) | 4.94 mm | 7.18 mm | 3.50 mm | 3.87 mm |
Cash used (since last report) | 24.23 mm | n/a | 33.68 mm | 48.92 mm | 23.82 mm | 26.33 mm |
Cash remaining | 56.51 mm | n/a | 47.06 mm | 31.83 mm | 56.93 mm | 54.41 mm |
Runway (months of cash) | 15.9 | n/a | 9.5 | 4.4 | 16.3 | 14.1 |
Institutional ownership, Q3 2023
13F holders | Current |
---|---|
Total holders | 45 |
Opened positions | 11 |
Closed positions | 5 |
Increased positions | 13 |
Reduced positions | 7 |
13F shares | Current |
---|---|
Total value | 9.91 bn |
Total shares | 26.99 mm |
Total puts | 3.90 k |
Total calls | 21.96 k |
Total put/call ratio | 0.2 |
Largest owners | Shares | Value |
---|---|---|
BGNE BeiGene | 12.15 mm | $43.39 mm |
Artal International S.C.A. | 4.00 mm | $12.96 mm |
LLY Lilly(Eli) & Co | 3.15 mm | $10.21 mm |
Baker Bros. Advisors | 1.17 mm | $1.62 bn |
Rock Springs Capital Management | 1.07 mm | $1.48 bn |
Adage Capital Partners GP, L.L.C. | 942.92 k | $1.30 bn |
Citadel Advisors | 644.22 k | $889.02 mm |
Samsara BioCapital | 602.20 k | $831.04 mm |
683 Capital Management | 490.00 k | $676.20 mm |
T. Rowe Price | 444.20 k | $613.00 k |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
29 Jan 24 | Cynthia Sirard | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.68 | 85,000 | 227.80 k | 85,000 |
29 Jan 24 | Patricia A. Martin | Stock Option Common Stock | Grant | Acquire A | No | No | 2.68 | 25,000 | 67.00 k | 25,000 |
29 Jan 24 | Lawlor Augustine | Employee Stock Option Common Stock | Grant | Acquire A | No | No | 2.68 | 85,000 | 227.80 k | 85,000 |
29 Jan 24 | Joseph Loscalzo | Stock Option Common Stock | Grant | Acquire A | No | No | 2.68 | 25,000 | 67.00 k | 25,000 |
News
12 Health Care Stocks Moving In Wednesday's After-Market Session
20 Mar 24
Baird Maintains Outperform on Leap Therapeutics, Lowers Price Target to $9
19 Mar 24
HC Wainwright & Co. Reiterates Buy on Leap Therapeutics, Maintains $7 Price Target
19 Mar 24
Leap Therapeutics: Q4 Earnings Insights
18 Mar 24
Leap Therapeutics Q4 EPS $(0.46) Beats $(0.55) Estimate, Cash Balance of $70.6M
18 Mar 24